A new report challenges assertions made during the committee’s recent hearing on the role of pharmacy benefit managers.
The FTC Wrongly Blames PBMs for High Drug Prices
The FTC fails to acknowledge the benefits of pharmacy benefit managers and wrong blames them for high drug prices.
Another Government Report Proves That PBMs Save Taxpayers Money
PBMs lower healthcare costs and another government agency overspent because a PBM was not used.
Attacking PBMs Won’t Result in Lower Drug Costs
SB 1550 will negatively impact Florida’s private sector healthcare market and ultimately harm patients.
The Cantwell-Grassley PBM Bill is a Wolf in Sheep’s Clothing
A Bill introduced in the Senate takes aim at PBMS and private sector healthcare.
House Committees Hold Oversight Hearings on COVID-19 Relief Fraud
Long overdue oversight hearings were finally held in the House of Representatives.
CCAGW Year in Review in the States
In 2022, CCAGW helped protect taxpayers with wins on data privacy, broadband spending, drug price controls, and reducing red tape.
The House Should Avoid Making the Senate’s Terrible Mistake on Healthcare
The House should avoid making the mistake of cutting the number of future cures and raising healthcare costs.
The Inflation Reduction Act Will Raise Drug Costs and Reduce Cures
Price controls in the Inflation Reduction Act will devastate future drug development and raise costs.
The Inflation Reduction Act Is a Fiscal Disaster
The Inflation Reduction Act of 2022 will raise taxes, increase spending, and prolong both inflation and the recession.